Vivek Subbiah, MD, shares his take home message regarding the treatment of patients with non–small cell lung cancer who harbor a RET fusion.
Vivek Subbiah, MD, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shares his take home message regarding the treatment of patients with non–small cell lung cancer (NSCLC) who harbor a RET fusion.
The main challenge lies in identifying patients who harbor a RET fusion or alteration, says Subbiah. RET accounts for 1% to 2% of all cases of NSCLC. Testing for this in NSCLC is important now following the FDA’s recent approval of selpercatinib (Retevmo) as treatment of patients with lung cancer harboring RET alterations.
Subbiah’s main message is that NSCLC is the poster child of precision oncology. The more physicians test for, the more we find. In order to win the war against lung cancer, Subbiah says we need to completely understand the disease, and comprehensive next-generation sequencing that includes all fusions and mutations is the first step.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More